for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evogene Ltd

EVGN.OQ

Latest Trade

1.66USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.34

 - 

3.18

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.66
Open
--
Volume
--
3M AVG Volume
0.91
Today's High
--
Today's Low
--
52 Week High
3.18
52 Week Low
1.34
Shares Out (MIL)
25.75
Market Cap (MIL)
149.36
Forward P/E
--
Dividend (Yield %)
--

Next Event

Evogene Ltd Extraordinary Shareholders Meeting

Latest Developments

More

Corteva Agriscience To Invest In Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

Evogene Reports Second Quarter Of 2019 Financial Results

Evogene Ltd QTRLY Loss Per Share $0.15

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evogene Ltd

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Industry

Biotechnology & Drugs

Contact Info

13 Gad Feinstein st.

Park Rehovot P.O.B 2100

+972.8.9311900

http://www.evogene.com/

Executive Leadership

Martin S. Gerstel

Chairman of the Board

Ofer Haviv

President, Chief Executive Officer

Alex Taskar

Chief Financial Officer

Ido Dor

Executive Vice President & General Manager Ag-Biologicals

Mark Kapel

Executive Vice President-Technology

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
27.55
Price To Book (MRQ)
1.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.88
LT Debt To Equity (MRQ)
6.19
Return on Investment (TTM)
-33.24
Return on Equity (TTM)
-30.53

Latest News

BRIEF-Evogene And Marrone Bio Innovations Announce Phase Advancement In Their Insect Control Collaboration

* EVOGENE AND MARRONE BIO INNOVATIONS ANNOUNCE PHASE ADVANCEMENT IN THEIR INSECT CONTROL COLLABORATION

BRIEF-Evogene Reports Q4 Loss Per Share $0.24

* EVOGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Evogene Announces Positive 2nd Year Field Trial Results In Corn Bio-Stimulant Ag-Biologicals Program

* EVOGENE ANNOUNCES POSITIVE 2ND YEAR FIELD TRIAL RESULTS IN CORN BIO-STIMULANT AG-BIOLOGICALS PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Evogene Q3 loss per share $0.20

* Evogene Ltd - in 2018, Evogene expects net cash usage of $14 million to $16 million

BRIEF-Evogene posts Q2 ‍loss per share $0.18​

* Total revenues for Q2 of 2017 were $1.2 million, compared to $1.8 million for Q2 in 2016

BRIEF-Evogene ltd - entered into a multiyear collaboration with DuPont Pioneer

* Evogene Ltd - entered into a multiyear collaboration with DuPont Pioneer

BRIEF-Evogene Ltd reaches an important milestone in its crop disease collaboration with Monsanto Company​

* Evogene Ltd- company reached an important milestone in its crop disease collaboration with Monsanto Company

BRIEF-Evogene announces positive results in insect control seed trait program

* Evogene Ltd announces positive results in insect control seed trait program and advancement to Phase-I of First Toxin against Western Corn Rootworm

BRIEF-Evogene reports Q1 loss per share $0.19

* Evogene Ltd - continues to expect that its net cash usage for full-year 2017 will be in range of $16 to $18 million

BRIEF-Marrone Bio Innovations to advance some novel bacteria, Evogene-identified related proteins into MBI'S bioinsecticide product development pipeline

* Evogene-Marrone bio innovations to advance some novel bacteria, Evogene-identified related proteins into MBI's bioinsecticide product development pipeline Source text for Eikon: Further company coverage:

BRIEF-Evogene Q4 revenue $1.2 million

* Evogene reports fourth quarter and full year 2016 financial results

BRIEF-Evogene, ICL Innovation enter multi-year R&D collaboration

* Evogene Ltd - co, ICL Innovation entered a multi-year research and development collaboration for discovery of novel crop enhancers Source text for Eikon: Further company coverage:

BRIEF-Migdal Insurance & Financial Holdings Ltd reports a 7.68 percent passive stake in Evogene Ltd as of Dec 31, 2016 - SEC filing

* Migdal Insurance & Financial Holdings Ltd reports a 7.68 percent passive stake in Evogene Ltd as of Dec 31, 2016 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Evogene Q3 loss per share $0.20

* Evogene reports third quarter 2016 financial results Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up